Allogeneic stem cell transplant is rarely used in multiple myeloma treatment, but for younger patients with high-risk myeloma, it could be a highly effective strategy with durable outcomes. Dr. Cristina Gasparetto from Duke University shares the rationale of this approach for a subset of myeloma patients and how improvements in reducing allo side effects (like graft vs. host disease) are making this type of transplant easier.  Thanks to our episode sponsor, Takeda Oncology